Menu Search
Equities

Nova Eye Medical Ltd

ELXMF:PKC

Nova Eye Medical Ltd

Actions
  • Price (USD)0.10
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Apr 25 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nova Eye Medical Limited is an Australia-based medical technology company that develops, manufactures, and sells a portfolio of proprietary ophthalmic treatment technologies and devices. The Company operates through three segments: AlphaRET, and Glaucoma surgical devices. The Company’s AlphaRET segment is responsible for the commercialization of the 2RT ophthalmic laser, which is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD). 2RT is a patented nano-pulse laser device that rejuvenates retinal structures compromised by AMD. The Glaucoma Surgical Devices segment includes the designing, manufacturing, marketing, and sale of the iTrack, iTrack Advance and the Molteno3 glaucoma surgical device. The Molteno3 glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term intraocular pressure (IOP) control in cases of severe glaucoma.

  • Revenue in AUD (TTM)23.45m
  • Net income in AUD-8.79m
  • Incorporated1970
  • Employees130.00
  • Location
    Nova Eye Medical Ltd3-4 Second AvenueADELAIDE 5095AustraliaAUS
  • Phone+61 88104-5200
  • Fax+61 88104-5231
  • Websitehttps://www.ellex.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.